iNKT-cell responses to glycolipids

Critical Reviews in Immunology

Volumn 25, Issue 3, 2005, Pages 183-213

  Parekh, Vrajesh V ^a   Wilson, Michael T ^a   Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD1d; Glycolipids; Immunomodulation; Immunotherapy; Innate immunity; Natural killer T cells

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD28 ANTIGEN; CD40 LIGAND; CERAMIDE DERIVATIVE; CYTOKINE; DNA VACCINE; ESTRADIOL; GALACTOSYLCERAMIDE; GAMMA INTERFERON ANTIBODY; GANGLIOSIDE GD3; GLYCOLIPID; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 7; MANNOSIDE; OCH; OXAZOLONE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ABORTION; ALLERGIC ASTHMA; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; CONTACT ALLERGY; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; HEPATITIS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; LUNG FIBROSIS; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE; TRYPANOSOMIASIS; TUBERCULOSIS;

ANIMALS; ANTIGENS, CD1; AUTOIMMUNE DISEASES; CARBOHYDRATE SEQUENCE; GALACTOSYLCERAMIDES; GLYCOLIPIDS; HUMANS; INFECTION; INFLAMMATION; KILLER CELLS, NATURAL; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 26844503175     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v25.i3.20     Document Type: Review

References (207)

1. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-305.
2. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272:50-53.
3. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15:535-562.
4. Joyce S. CD1d and natural T cells: how their properties jump-start the immune system. Cell Mol Life Sci 2001; 58:442-469.
5. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003; 21:483-513.
6. Van Kaer L. Regulation of immune responses by CD1d-restricted natural killer T cells. Immunol Res 2004; 30:139-153.
7. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004; 22:817-890.
8. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114:1379-1388.
9. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 26:877-900.
10. Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L, Kronenberg M, Locksley RM. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 2003; 198:1069-1076.
11. Bendelac A, Bonneville M, Kearney JF. Autoreactivity by design: innate B and T lymphocytes. Nat Rev Immunol 2001; 1:177-186.
12. Karadimitris A, Gadola S, Altamirano M, Brown D, Woolfson A, Klenerman P, Chen JL, Koezuka Y, Roberts IA, Price DA, Dusheiko G, Milstein C, Fersht A, Luzzatto L, Cerundolo V. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci U S A 2001; 98:2950-2952.
13. Park SH, Bendelac A. CD1-restricted T-cell responses and microbial infection. Nature 2000; 406:788-792.
14. Gumperz JE, Brenner MB. CD1-specific T cells in microbial immunity. Curr Opin Immunol 2001; 13:471-480.
15. Skold M, Behar SM. Role of CD1d-restricted NKT cells in microbial immunity. Infect Immun 2003; 71:5447-5455.
16. Skold M, Behar SM. The role of group 1 and group 2 CD1-restricted T cells in microbial immunity. Microbes Infect 2005; 7:544-551.
17. Brutkiewicz RR, Sriram V. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol 2002; 41:287-298.
18. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells-conductors of tumor immunity? Curr Opin Immunol 2002; 14:165-171.
19. Smyth MJ, Godfrey DI. NKT cells and tumor immunity-a double-edged sword. Nat Immunol 2000; 1:459-460.
20. Swann J, Crowe NY, Hayakawa Y, Godfrey DI, Smyth MJ. Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunol Cell Biol 2004; 82:323-331.
21. Hammond KJ, Kronenberg M. Natural killer T cells: natural or unnatural regulators of autoimmunity? Curr Opin Immunol 2003; 15:683-689.
22. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003; 3:211-222.
23. Mars LT, Novak J, Liblau RS, Lehuen A. Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks. Trends Immunol 2004; 25:471-476.
24. Major AS, Van Kaer L. The role of natural killer T cells in atherosclerosis. Curr Immunol Rev 2005; In press.
25. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, Taniguchi M, Grusby MJ, DeKruyff RH, Umetsu DT. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003; 9:582-588.
26. Lisbonne M, Diem S, de Castro Keller A, Lefort J, Araujo LM, Hachem P, Fourneau J-M, Sidobre S, Kronenberg M, Taniguchi M, Van Endert P, Dy M, Askenase P, Russo M, Vargaftig BB, Herbelin A, Leite-de-Moraes MC. Cutting edge: invariant Vα14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J Immunol 2003; 171:1637-1641.
27. Campos RA, Szczepanik M, Itakura A, Akahira-Azuma M, Sidobre S, Kronenberg M, Askenase PW. Cutaneous immunization rapidly activates liver invariant Vα14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact hypersensitivity. J Exp Med 2003; 198:1785-1796.
28. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002; 17:629-638.
29. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 2000; 97:5498-5503.
30. Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, Segawa T, Maeda M, Hamuro J, Nakayama T, Taniguchi M, Yagita H, Van Kaer L, Onoe K, Denhardt D, Rittling S, Uede T. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004; 21:539-550.
31. Oh K, Kim S, Park SH, Gu H, Roopenian D, Chung DH, Kim YS, Lee DS. Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity. J Immunol 2005; 174:2030-2036.
32. Sonoda KH, Taniguchi M, Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells. J Immunol 2002; 168:2028-2034.
33. Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, Strober S. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189:1073-1081.
34. Sonoda KH, Exley M, Snapper S, Balk SP, Stein-Streilein J. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med 1999; 190:1215-1226.
35. Hong S, Van Kaer L. Immune privilege: keeping an eye on natural killer T cells. J Exp Med 1999; 190:1197-1200.
36. Boyson JE, Rybalov B, Koopman LA, Exley M, Balk SP, Racke FK, Schatz F, Masch R, Wilson SB, Strominger JL. CD1d and invariant NKT cells at the human maternal-fetal interface. Proc Natl Acad Sci U S A 2002; 99:13741-13746.
37. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000; 1:521-525.
38. + Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J Clin Invest 2000; 105:1761-1767.
39. Seino Ki K, Fukao K, Muramoto K, Yanagisawa K, Takada Y, Kakuta S, Iwakura Y, Van Kaer L, Takeda K, Nakayama T, Taniguchi M, Bashuda H, Yagita H, Okumura K. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci U S A 2001; 98:2577-2581.
40. + invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J Immunol 2004; 173:1043-1050.
41. Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 1999; 17:297-329.
42. Joyce S, Van Kaer L. CD1-restricted antigen presentation: an oily matter. Curr Opin Immunol 2003; 15:95-104.
43. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 1997; 277:339-345.
44. + T lymphocytes. Science 1995; 268:863-865.
45. + T cells in major histocompatibility complex class II-deficient mice. J Exp Med 1995; 182:993-1004.
46. + targets. J Immunol 1998; 160:3681-3688.
47. Park SH, Roark JH, Bendelac A. Tissue-specific recognition of mouse CD1 molecules. J Immunol 1998; 160:3128-3134.
48. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997; 278:1626-1629.
49. Natori T, Koezuka Y, Higa T. Agelasphins, novel α- galactosylceramides from the marine sponge Agelas mauritianus. Tetrahedron Lett 1993; 34:5591-5592.
50. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995; 7:529-534.
51. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, Kronenberg M. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188:1521-1528.
52. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998; 188:1529-1534.
53. Motsinger A, Azimzadeh A, Stanic AK, Johnson RP, Van Kaer L, Joyce S, Unutmaz D. Identification and simian immunodeficiency virus infection of CD1d-restricted macaque natural killer T cells. J Virol 2003; 77:8153-8158.
54. Bezbradica JS, Stank AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, Unutmaz D, Van Kaer L, Joyce S. Distinct roles of dendritic cells and B cells in Vα14Ja18 natural T cell activation in vivo. J Immunol 2005; 174:4694-4705.
55. Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci U S A 2005; 102:1127-1132.
56. Ikarashi Y, Mikami R, Bendelac A, Terme M, Chaput N, Terada M, Tursz T, Angevin E, Lemonnier FA, Wakasugi H, Zitvogel L. Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production. J Exp Med 2001; 194:1179-1186.
57. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004; 199:1607-1618.
58. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189:1121-1128.
59. Kawano T, Tanaka Y, Shimizu E, Kaneko Y, Kamata N, Sato H, Osada H, Sekiya S, Nakayama T, Taniguchi M. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand. Int Immunol 1999; 11:881-887.
60. Burdin N, Brossay L, Degano M, Iijima H, Gui M, Wilson IA, Kronenberg M. Structural requirements for antigen presentation by mouse CD1. Proc Natl Acad Sci U S A 2000; 97:10156-10161.
61. Naidenko OV, Maher JK, Ernst WA, Sakai T, Modlin RL, Kronenberg M. Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J Exp Med 1999; 190:1069-1080.
62. Brossay L, Naidenko O, Burdin N, Matsuda J, Sakai T, Kronenberg M. Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells. J Immunol 1998; 161:5124-5128.
63. Kinjo Y, Wu DY, Kim G, Xing G-W, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong C-H, Kronenberg M. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005; 434:520-525.
64. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413:531-534.
65. Goff RD, Gao Y, Mattner J, Zhou D, Yin N, Cantu CI, Teyton L, Bendelac A, Savage PB. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004; 126:13602-13603.
66. Parekh W, Singh AK, Wilson MT, Olivares-Villagomez D, Bezbradica JS, Inazawa H, Ehara H, Sakai T, Serizawa I, Wu L, Wang CR, Joyce S, Van Kaer L. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J Immunol 2004; 173:3693-3706.
67. Oki S, Chiba A, Yamamura T, Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 2004; 113:1631-1640.
68. Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, Fujiwara N, Arias I, Miyake S, Yamamura T, Chang YT, Besra GS, Porcelli SA. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc Natl Acad Sci U S A 2005; 102:3383-3388.
69. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J Exp Med 2003; 198:1631-1641.
70. Stanic AK, Shashidharamurthy R, Bezbradica JS, Matsuki N, Yoshimura Y, Miyake S, Choi EY, Schell TD, Van Kaer L, Tevethia SS, Roopenian DC, Yamamura T, Joyce S. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T (iNKT) cell receptor. J Immunol 2003; 171:4539-4551.
71. Cantu C, Benlagha K, Savage PB, Bendelac A, Teyton L. The paradox of immune molecular recognition of p α-galactosylceramide: low affinity, low specificity for CD1d, high affinity for αβ TCRs. J Immunol 2003; 170:4673-4682.
72. Sidobre S, Hammond KJ, Benazet-Sidobre L, Maltsev SD, Richardson SK, Ndonye RM, Howell AR, Sakai T, Besra GS, Porcelli SA, Kronenberg M. The T cell antigen receptor expressed by Vα14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc Natl Acad Sci U S A 2004; 101:12254-12259.
73. Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EWJ, Murphy WJ, Wiltrout RH. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 2004; 172:943-953.
74. Joyce S, Woods AS, Yewdell JW, Bennink JR, De Silva AD, Boesteanu A, Balk SP, Cotter RJ, Brutkiewicz RR. Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 1998; 279:1541-1544.
75. Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, Koezuka Y, Porcelli SA, Cardell S, Brenner MB, Behar SM. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000; 12:211-221.
76. Rauch J, Gumperz J, Robinson C, Skold M, Roy C, Young DC, Lafleur M, Moody DB, Brenner MB, Costello CE, Behar SM. Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J Biol Chem 2003; 278:47508-47515.
77. Schofield L, McConville MJ, Hansen D, Campbell AS, Fraser-Reid B, Grusby MJ, Tachado SD. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 1999; 283:225-229.
78. Molano A, Park SH, Chiu YH, Nosseir S, Bendelac A, Tsuji M. Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses. J Immunol 2000; 164:5005-5009.
79. Procopio DC, Almeida IC, Torrecilhas AC, Cardoso JE, Teyton L, Travassos LR, Bendelac A, Gazzinelli RT. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. J Immunol 2002; 169:3926-3933.
80. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 2003; 198:173-181.
81. + T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci U S A 2002; 99:8197-8202.
82. Stanic AK, De Silva AD, Park JJ, Sriram V, Ichikawa S, Hirabyashi Y, Hayakawa K, Van Kaer L, Brutkiewicz RR, Joyce S. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by β-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci U S A 2003; 100:1849-1854.
83. Zhou D, Mattner J, Cantu C, Schrantz N, Yin N, Gao Y, Sagiv Y, Hudspeth K, Wu Y, Yamashita T, Teneberg S, Wang D, Proia R, Levery SB, Savage PB, Teyton L, Bendelac A. Lysosomal glycophingolipid recognition by NKT cells. Science 2004; 306:1786-1789.
84. Van Kaer L, Joyce S. Innate immunity: NKT cells in the spotlight. Curr Biol 2005; In press.
85. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003; 4:1230-1237.
86. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
87. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278:1623-1626.
88. Mattner J, DeBord KL, Ismail N, Goff RD, Cantu CI, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N, Hoebe K, Schneewind O, Walker D, Buetler B, Teyton L, Savage PB, Bendelac A. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434:525-529.
89. Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, Hurwitz R, Kursar M, Bonneville M, Kaufmann SHE, Schaible UE. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci U S A 2004; 101:10685-10690.
90. Amprey JL, Im JS, Turco SJ, Murray HW, Illarionov PA, Besra GS, Porcelli SA, Spath GF. A subset of liver NKT cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med 2004; 200:895-904.
91. Haefher B. Drugs from the deep: marine natural products as drug candidates. Drug Discov Today 2003; 8:536-544.
92. Perola O, Nousiainen T, Suomalainen S, Aukee S, Karkkainen UM, Kauppinen J, Ojanen T, Katila ML. Recurrent Sphingomonas paucimobilis-bacteraemia associated with a multi-bacterial water-borne epidemic among neutropenic patients. J Hosp Infect 2002; 50:196-201.
93. Van Kaer L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005; 5:31-42.
94. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002; 195:625-636.
95. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human Vα24 natural killer T cells. J Exp Med 2002; 195:637-641.
96. Eberl G, MacDonald HR. Rapid death and regeneration of NKT cells in anti-CD3epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 1998; 9:345-353.
97. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000; 30:985-992.
98. Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR, Joyce S, Wick MJ, Van Kaer L. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci U S A 2003; 100:10913-10918.
99. Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJL, Hayakawa K, Sidobre S, Keating R, Kronenberg M, Smyth MJ, Godfrey DI. Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J Immunol 2003; 171:4020-4027.
100. Harada M, Seino KI, Wakao H, Sakata S, Ishizuka Y, Ito T, Kojo S, Nakayama T, Taniguchi M. Down-regulation of the invariant Vα14 antigen receptor in NKT cells upon activation. Int Immunol 2004; 16:241-247.
101. Schonrich G, Kalinke U, Momburg F, Malissen M, Schmitt-Verhulst AM, Malissen B, Hammerling GJ, Arnold B. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 1991; 65:293-304.
102. Seino K, Harada M, Taniguchi M. NKT cells are relatively resistant to apoptosis. Trends Immunol 2004; 25:219-221.
103. Giaccone G, Punt CJA, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BME, Scheper RJ, van der Vliet HJJ, van den eertwegh AJM, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM. A phase I study of natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8:3702-3709.
104. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103:383-389.
105. Park SH, Kyin T, Bendelac A, Carnaud C. The contribution of NKT cells, NK cells, and other γ-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 2003; 170:1197-1201.
106. Sandberg JK, Bhardwaj N, Nixon DF. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Vα24 NKT cell compartment. Eur J Immunol 2003; 33:588-596.
107. Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, Koezuka Y, Van Kaer L. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999; 163:2373-2377.
108. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y, Van Kaer L. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7:1052-1056.
109. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001; 7:1057-1062.
110. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat Immunol 2002; 3:867-874.
111. Matsuda JL, Gapin L, Baron JL, Sidobre S, Stetson DB, Mohrs M, Locksley RM, Kronenberg M. Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A 2003; 100:8395-8400.
112. + T cells. Cell 1992; 71:1205-1214.
113. Brutkiewicz RR, Bennink JR, Yewdell JW, Bendelac A. TAP-independent, β2-microglobulin-dependent surface expression of functional mouse CD1.1. J Exp Med 1995; 182:1913-1919.
114. Hayakawa Y, Berzins SP, Crowe NY, Godfrey DI, Smyth MJ. Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors. Nat Immunol 2004; 5:590-596.
115. Yang J-Q, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated α-galactosylceramide administration results in expansion of Vα14 NKT cells and alleviates inflammatory dermatitis in MKL-lpr/lpr mice. J Immunol 2003; 171:4439-4446.
116. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999; 163:4647-4650.
117. Nakagawa R, Motoki K, Nakamura H, Ueno H, Iijima R, Yamauchi A, Tsuyuki S, Inamoto T, Koezuka Y. Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol Res 1998; 10:561-568.
118. Wesley JD, Robbins SH, Sidobre S, Kronenberg M, Terrizzi S, Brossay L. Cutting edge: IFN-γ signaling to macrophages is required for optimal Vα14i NK T/NK cell cross-talk. J Immunol 2005; 174:3864-3868.
119. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198:267-279.
120. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y, Balk SB, Strominger JL, Clare-Salzer M, Wilson SB. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A 2001; 98:13838-13843.
121. Kitamura H, Ohta A, Sekimoto M, Sato M, Iwakabe K, Nakui M, Yahata T, Meng H, Koda T, Nishimura S, Kawano T, Taniguchi M, Nishimura T. α-Galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol 2000; 199:37-42.
122. + T cells upon NK T or T cell activation. J Immunol 2000; 165:4305-4311.
123. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nakui M, Sekimoto M, Koda T. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000; 12:987-994.
124. Burdin N, Brossay L, Kronenberg M. Immunization with α- galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999; 29:2014-2025.
125. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B. Schistosoma mansoni and α-galactosylceramide: prophylactic effect of Th1 immune suppression in a mouse model of Graves' hyperthyroidism. J Immunol 2004; 173:2167-2173.
126. Singh AK, Yang J-Q, Parekh VV, Wei J, Wang CR, Joyce S, Singh RR, Van Kaer L. The natural killer T cell ligand α-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol 2005; 35:1143-1154.
127. Cui J, Watanabe N, Kawano T, Yamashita M, Kamata T, Shimizu C, Kimura M, Shimizu E, Koike J, Koseki H, Tanaka Y, Taniguchi M, Nakayama T. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. J Exp Med 1999; 190:783-792.
128. + T cells. J Immunol 1999; 162:7067-7074.
129. Leite-De-Moraes MC, Moreau G, Arnould A, Machavoine F, Garcia C, Papiernik M, Dy M. IL-4-producing NK T cells are biased towards IFN-γ production by IL-12. Influence of the microenvironment on the functional capacities of NK T cells. Eur J Immunol 1998; 28:1507-1515.
130. Leite-de-Moraes MC, Hameg A, Pacilio M, Koezuka Y, Taniguchi M, Van Kaer L, Schneider E, Dy M, Herbelin A. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. J Immunol 2001; 166:945-951.
131. Gourdy P, Araujo LM, Garmy-Susini B, Diem S, Laurell H, Leite-De-Moraes M, Dy M, Arnal JF, Bayard F, Herbelin A. Relevance of sexual dipmorphism to regulatory T cells: estradiol promotes IFN-γ production by invariant natural killer T cells. Blood 2004; 105:2415-2420.
132. Pal E, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells. J Immunol 2001; 166:662-668.
133. Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001; 166:6012-6018.
134. + T cells upon NKR-P1 cross-linking. J Exp Med 1996; 183:2391-2396.
135. Ota T, Takeda K, Akiba H, Hayakawa Y, Ogasawara K, Ikarashi Y, Miyake S, Wakasugi H, Yamamura T, Kronenberg M, Raulet DH, Kinoshita K, Yagita H, Smyth MJ, Okumura K. IFN-γ-mediated negative feedback regulation of NKT cell function by CD94/NKG2. Blood 2005; In press.
136. Wilson MT, Singh AK, Van Kaer L. Immunotherapy with ligands of natural killer T cells. Trends Mol Med 2002; 8:225-231.
137. Hayakawa Y, Godfrey DI, Smyth MJ. α-Galactosylceramide: potential immunomodulatory activity and future application. Curr Med Chem 2004; 11:241-252.
138. Hayakawa Y, Rovero S, Forni G, Smyth MJ. α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci U S A 2003; 100:9464-9469.
139. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y, Taniguchi M. Natural killer-like non-specific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci U S A 1998; 95:5690-5693.
140. Kobayashi E, Motoki K, Yamaguchi Y, Uchida T, Fukushima H, Koezuka Y. Enhancing effects of α-, β-monoglycosylceramides on natural killer cell activity. Bioorg Med Chem 1996; 4:615-619.
141. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 2002; 99:1259-1266.
142. Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, Saiki I, Okumura K. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur J Immunol 2001; 31:1720-1727.
143. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 1999; 163:2387-2391.
144. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I. IFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide. Blood 2002; 100:1728-1733.
145. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171:5140-5147.
146. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, Mathew B, Schmidt RR, Lunt SJ, Williams KJ, Stratford IJ, Harris AL, Cerundolo V. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 2004; 114:1800-1811.
147. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11:1910-1917.
148. Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. Infect Immun 2002; 70:6302-6309.
149. Nieuwenhuis EE, Matsumoto T, Exley M, Schleipman RA, Glickman J, Bailey DT, Corazza N, Colgan SP, Onderdonk AB, Blumberg RS. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002; 8:588-593.
150. + natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol 2003; 33:3322-3330.
151. Van Dommelen SL, Tabarias HA, Smyth MJ, Degli-Eposti MA. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J Virol 2003; 77:1877-1884.
152. + T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 2002; 76:4294-4303.
153. Exley MA, Bigley NJ, Cheng O, Tahir SM, Smiley ST, Carter QL, Stills HF, Grusby MJ, Koezuka Y, Taniguchi M, Balk SP. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J Leukoc Biol 2001; 69:713-718.
154. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192:921-930.
155. Kakimi K, Lane TE, Chisari FV, Guidotti LG. Cutting edge: inhibof hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol 2001; 167:6701-6705.
156. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T, Taniguchi M, Bendelac A, Van Kaer L, Koezuka Y, Tsuji M. α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci U S A 2000; 97:8461-8466.
157. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002; 195:617-624.
158. Duthie MS, Kahn SJ. Treatment with α-galactosylceramide before Trypanosoma cruzi infection provides protection or induces failure to thrive. J Immunol 2002; 168:5778-5785.
159. Miyahira Y, Katae M, Takeda K, Yagita H, Okumura K, Kobayashi S, Takeuchi T, Kamiyama T, Fukuchi Y, Aoki T. Activation of natural killer T cells by α-galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi. Infect Immun 2003; 71:1234-1241.
160. + natural killer T cells by α-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect Immun 2001; 69:213-220.
161. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997; 7:727-738.
162. Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 2001; 19:131-161.
163. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001; 194:313-320.
164. Mizuno M, Masumura M, Tomi C, Chiba A, Oki S, Yamamura T, Miyake S. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J Autoimmun 2004; 23:293-300.
165. Mi Q-S, Ly D, Zucker P, McGarry M, Delovitch TL. Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T cells. Diabetes 2004; 53:1303-1310.
166. Bollyky PL, Wilson SB. CD1d-restricted T-cell subsets and dendritic cell function in autoimmunity. Immunol Cell Biol 2004; 82:307-314.
167. Chen YG, Choisy-Rossi CM, Holl TM, Chapman HD, Besra GS, Porcelli SA, Shaffer DJ, Roopenian D, Wilson SB, Serreze DV. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005; 174:1196-1204.
168. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85:299-302.
169. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999; 24:511-514.
170. Owens T, Wekerle H, Antel J. Genetic models for CNS inflammation. Nat Med 2001; 7:161-166.
171. Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001; 194:1801-1811.
172. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001; 194:1789-1799.
173. Furlan R, Bergami A, Cantarella D, Brambilla E, Taniguchi M, Dellabona P, Casorati G, Martino G. Activation of invariant NKT cells by α-GalCer administration protects mice from MOG35-55 induced EAE: critical roles for administration route and IFN-γ. Eur J Immunol 2003; 33:1830-1838.
174. + T cells that promptly produce interleukin 4. Proc Natl Acad Sci U S A 1995; 92:11931-11934.
175. Holmdahl R. Dissection of the genetic complexity of arthritis using animal models. J Autoimmun 2003; 21:99-103.
176. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of α-galactosylceramide. Arthritis Rheum 2004; 50:305-313.
177. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303-306.
178. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003; 112:1211-1222.
179. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH)-releasing hormone receptor: interaction with TSH and autoantibodies. Endocrine Rev 1998; 19:673-716.
180. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20:495-549.
181. Saubermann LJ, Beck P, De Jong YP, Pitman RS, Ryan MS, Kim HS, Exley M, Snapper S, Balk SP, Hagen SJ, Kanauchi O, Motoki K, Sakai T, Terhorst C, Koezuka Y, Podolsky DK, Blumberg RS. Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000; 119:119-128.
182. Ueno Y, Tanaka S, Sumii M, Miyake S, Tazuma S, Taniguchi M, Yamamura T, Chayama K. Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of Vα14 natural killer T cells in mice. Inflamm Bowel Dis 2005; 11:35-41.
183. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22:361-403.
184. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
185. Ostos MA, Recalde D, Zakin MM, Scott-Algara D. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 2002; 519:23-29.
186. Melian A, Geng YJ, Sukhova GK, Libby P, Porcelli S. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am J Pathol 1999; 155:775-786.
187. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, Berne GP. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004; 199:417-422.
188. Nakai Y, Iwabuchi K, Fujii S, Ishimori N, Dashtsoodol N, Watano K, Mishima T, Iwabuchi C, Tanaka S, Bezbradica JS, Nakayama T, Taniguchi M, Miyake S, Yamamura T, Kitabatake A, Joyce S, Van Kaer L, Onoe K. Natural killer T cells accelerate atherogenesis in mice. Blood 2004; 104:2051-2059.
189. Major AS, Wilson MT, McCaleb JL, Ru Su Y, Stanic AK, Joyce S, Van Kaer L, Fazio S, Linton MF. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24:2351-2357.
190. van den Blink B, Jansen HM, Peppelenbosch MP. Idiopathic pulmonary fibrosis: molecular mechanisms and possible therapeutic strategies. Arch Immunol Ther Exp 2000; 48:539-545.
191. Kimura T, Ishii Y, Morishima Y, Shibuya A, Shibuya K, Taniguchi M, Mochizuki M, Hegab AE, Sakamoto T, Nomura A, Sekizawa K. Treatment with α-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis. J Immunol 2004; 172:5782-5789.
192. Eisen HN, Orris L, Belman S. Elicitation of delayed allergic skin reactions with haptens: the dependence of elicitation on hapten combination with protein. J Exp Med 1952; 95:473-487.
193. Nieuwenhuis EES, Gillessen S, Scheper RJ, Exley MA, Taniguchi M, Balk SP, Strominger JL, Dranoff G, Blumberg RS, Wilson SB. CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp Dermatol 2005; 14:250-258.
194. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22:789-815.
195. Bilenki L, Yang J, Fan Y, Wang S, Yang X. Natural killer T cells contribute to airway eosinophilic inflammation induced by ragweed through enhanced IL-4 and eotaxin production. Eur J Immunol 2004; 34:345-354.
196. Matsuda H, Suda T, Sato J, Nagata T, Koide Y, Chida K, Nakamura H. α-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am J Respir Cell Mol Biol 2005; In press.
197. Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12:809-837.
198. Chung Y, Chang WS, Kim S, Kang CY. NKT cell ligand α- galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur J Immunol 2004; 34:2471-2479.
199. Kim JO, Kim DH, Chang WS, Hong C, Park SH, Kim S, Kang CY. Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model. J Allergy Clin Immunol 2004; 114:1332-1338.
200. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411:385-389.
201. Morecki S, Panigrahi S, Pizov G, Yacovlev E, Gelfand Y, Eizik O, Slavin S. Effect of KRN7000 on induced graft-vs-host disease. Exp Hematol 2004; 32:630-637.
202. Hashimoto D, Asakura S, Miyake S, Yamamura T, Van Kaer L, Liu C, Tanimoto M, Teshima T. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 2005; 174:551-556.
203. Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K, Abo T. Activation of hepatic NKT cells and subsequent liver injury following administration of a α-galactosylceramide. Eur J Immunol 2000; 30:1919-1928.
204. Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice. J Immunol 2001; 166:6578-6584.
205. + T cells: their cytokine production and hepatotoxicity in vivo and in vitro. J Immunol 2002; 169:6127-6132.
206. Ito K, Karasawa M, Kawano T, Akasaka T, Koseki H, Akutsu Y, Kondo E, Sekiya S, Sekikawa K, Harada M, Yamashita M, Nakayama T, Taniguchi M. Involvement of decidual Vα14 NKT cells in abortion. Proc Natl Acad Sci U S A 2000; 97:740-744.
207. Wang S, Li C, Kawamura H, Watanabe H, Abo T. Unique sensitivity to α-galactosylceramide of NKT cells in the uterus. Cell Immunol 2002; 215:98-105.